The CAR-T Congress gathers thought leaders from biotech, big pharma, academia and investment to address the challenges and opportunities of CAR-T therapies in both liquid and solid tumors.
Builing on the success of our global series, the CAR-T congress will discuss how to overcome the challenges including toxicity, dosing limitations, re-treatment strategies, scalability, manufacturing, and pricing strategies.
This is a chance to discover the new bodies of evidence defining the extent to which Car-T is efficacious, and how it compares to standard treatments. Sessions will explore advances in genome editing tools, the new methods in allogeneic and autologous process development and the pre-clinical concepts that will pave the way for neo-antigen discovery.
Introducing dedicated partnering & networking sessions, with high level workshops to navigate the investment landscape & meet emerging companies. Join us for a rare opportunity to hear first-hand about the latest innovative developments shaping the industry.